Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TROPHAMET, a Phase I/II Trial of Avelumab and METhotrexate in Low-risk Gestational TROPHoblastic Neoplasias as First Line Treatment

NCT04396223 is registered in ClinicalTrials.gov with Hospices Civils de Lyon as lead sponsor.

NCT NCT04396223
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04396223 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TROPHAMET, a Phase I/II Trial of Avelumab and METhotrexate in Low-risk Gestational TROPHoblastic Neoplasias as First Line Treatment
Lead sponsor
Hospices Civils de Lyon
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 12, 2020
Completion date
October 12, 2028
Enrollment
26 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

gestational trophoblastic neoplasias (gtn)